FOR THE ACUTE TREATMENT OF MIGRAINE AND PREVENTIVE TREATMENT OF EPISODIC MIGRAINE IN ADULTS[1]

Nurtec® ODT (rimegepant) orally disintegrating tablets 75 mg

Nurtec® ODT (rimegepant) is the only oral CGRP receptor antagonist approved for acute and preventive treatment with Preferred status on Cigna's commercial formulary[2-5,†]

Formulary coverage for oral CGRP receptor antagonists

DRUG NAME	COVERAGE DETAILS[1,3-6]	
	Acute treatment	Preventive treatment*
Nurtec ODT 75 mg	• Prior trial of 1 triptan required • Preferred status	• Prior trial of 2 agents for migraine prophylaxis[‡] • Preferred status
Ubrelvy® (ubrogepant) 50 mg, 100 mg	• Prior trial of 1 triptan required • Preferred status	Not indicated

CGRP, calcitonin gene-related peptide; ODT, orally disintegrating tablet.

*Preventive treatment of episodic migraine only. †Managed Markets Insights & Technology LLC as of 07/21. ‡Prior prophylactic therapies must be from different classes. Examples include angiotensin receptor blockers, angiotensin converting enzyme inhibitors, anticonvulsants, beta-blockers, calcium channel blockers, tricyclic antidepressants, or other depressants.

INDICATION

Nurtec ODT is indicated in adults for the:

- acute treatment of migraine with or without aura
- preventive treatment of episodic migraine

IMPORTANT SAFETY INFORMATION

Contraindications: Hypersensitivity to Nurtec ODT or any of its components.

Warnings and Precautions: If a serious hypersensitivity reaction occurs, discontinue Nurtec ODT and initiate appropriate therapy. Serious hypersensitivity reactions have included dyspnea and rash, and can occur days after administration.

Adverse Reactions: The most common adverse reactions were nausea (2.7% in patients who received Nurtec ODT compared to 0.8% in patients who received placebo) and abdominal pain/dyspepsia (2.4% in patients who received Nurtec ODT compared to 0.8% in patients who received placebo). Hypersensitivity, including dyspnea and rash, occurred in less than 1% of patients treated with Nurtec ODT.

Drug Interactions: Avoid concomitant administration of Nurtec ODT with strong inhibitors of CYP3A4, strong or moderate inducers of CYP3A or inhibitors of P-gp or BCRP. Avoid another dose of Nurtec ODT within 48 hours when it is administered with moderate inhibitors of CYP3A4.

Use in Specific Populations: *Pregnant/breast feeding*: It is not known if Nurtec ODT can harm an unborn baby or if it passes into breast milk. *Hepatic impairment*: Avoid use of Nurtec ODT in persons with severe hepatic impairment. *Renal impairment*: Avoid use in patients with end-stage renal disease.

Please see accompanying full Prescribing Information.

References: 1. Nurtec ODT. Package Insert. Biohaven Pharmaceuticals Inc. **2.** Croop L, Lipton RB, Kudrow D, et al. Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo-controlled trial. *Lancet*. Published online December 15, 2020. doi:10.1016/S0140-6736(20)32544-7. **3.** Cigna website. Cigna standard 3-tier prescription drug list. https://www.cigna.com/static/www-cigna-com/docs/individuals-families/member-resources/prescription/value-3-tier.pdf. Updated June 1, 2021. Accessed September 2, 2021. **4.** Cigna website. Drug and biologic coverage policy: rimegepant. https://static.cigna.com/assets/chcp/pdf/coveragePolicies/pharmacy/ip_0147_coveragepositioncriteria_rimegepant.pdf. Updated August 1, 2021. Accessed September 2, 2021. **5.** Cigna website. Drug and biologic coverage policy: ubrogepant. https://static.cigna.com/assets/chcp/pdf/coveragePolicies/pharmacy/ip_0148_coveragepositioncriteria_ubrogepant.pdf. Updated July 1, 2021. Accessed September 2, 2021. **6.** Ubrelvy. Package insert. Allergan, Inc.

US-RIMODT-2100787 09/02/2021

biohaven™ pharmaceuticals